Abstract：
:Malignant pleural effusions (MPEs) are a significant source of cancer-related morbidity. Over 150,000 patients in the United States suffer from breathlessness and diminished quality of life due to MPE each year. Current management strategies are of mostly palliative value and focus on symptom control; they do not address the pathobiology of the effusion, nor do they improve survival. Further elucidation of the pathophysiological mechanisms, coupled with the development of novel treatments such as intrapleural chemotherapeutics targeting this process, has the potential to greatly improve the efficacy of our current management options. Vascular endothelial growth factor-A (VEGF-A) has been implicated as a critical cytokine in the formation of malignant pleural effusions. Elevated levels of VEGF produced by tumor cells, mesothelial cells, and infiltrating immune cells result in increased vascular permeability, cancer cell transmigration, and angiogenesis. Therefore antiangiogenic therapies such as Bevacizumab, a monoclonal antibody targeting VEGF-A, may have a potential role in the management of malignant pleural effusions. Herein we review the pathogenesis and potential treatment strategies of malignant pleural effusions, with a focus on angiogenesis and antiangiogenic therapeutics.
journal_name
Curr Oncol Repjournal_title
Current oncology reportsauthors
Bradshaw M,Mansfield A,Peikert Tdoi
10.1007/s11912-013-0315-7subject
Has Abstractpub_date
2013-06-01 00:00:00pages
207-16issue
3eissn
1523-3790issn
1534-6269journal_volume
15pub_type
杂志文章,评审abstract：:Epidemiologic studies supported by molecular technology have provided sufficient evidence of the causal role of some human papillomavirus (HPV) infections in the development of cervical cancer. The finding is consistent universally, and HPV has been proposed as the first identified necessary cause of cervical cancer. ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-002-0079-y
更新日期：2002-03-01 00:00:00
abstract：PURPOSE OF REVIEW:Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy. Here, we review evidence regarding ALK inhibitors (ALKi): clinical activity, safety profiles, financial...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-00989-6
更新日期：2021-01-02 00:00:00
abstract：:Proton beam radiation therapy (PBRT) has unique physical properties (e.g., Bragg Peak) that limit the amount of normal tissue irradiated in the head and neck region while maximizing the radiation delivered to the tumor. Radiation therapy is commonly used in both the primary and adjuvant setting for many head and neck ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-010-0089-0
更新日期：2010-05-01 00:00:00
abstract：:The number of patients given neoadjuvant chemotherapy (NAC) followed by fertility-sparing surgery in cervical cancer is still scarce. Only a few centres perform these procedures, and thus, such procedures remain largely in the experimental stage. Patients that do not fulfil the criteria for standard fertility-sparing ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-015-0446-0
更新日期：2015-01-01 00:00:00
abstract：PURPOSE OF REVIEW:The knowledge base of malignant cell growth and resulting targets is rapidly increasing every day. Clonal theory is essential to understand the changes required for a cell to become malignant. These changes are then clues to therapeutic intervention strategies. Immune system optimization is a critical...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-017-0625-2
更新日期：2017-08-12 00:00:00
abstract：:Treatment of Hodgkin's disease (HD) is strictly dependent on stage. Historically, early-stage HD included the limited stages I, II, and IIIA (according to the Cotswolds modification of the Ann Arbor classsification), whereas advanced HD included stage III with B symptoms and stage IV. It was then observed that early-s...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-001-0062-z
更新日期：2001-05-01 00:00:00
abstract：PURPOSE OF REVIEW:Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise. RECENT FINDINGS:A limited body of preclin...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-017-0586-5
更新日期：2017-04-01 00:00:00
abstract：:The introduction of targeted therapies, specifically those that target the VEGF receptor (VEGFR), PDGF receptor (PDGFR) and the mTOR pathways, has significantly changed the approach to patients with unresectable renal cell cancer (RCC). However, drug resistance develops through bypassing of targeted pathways. Regorafe...
journal_title：Current oncology reports
pub_type： 杂志文章
doi：10.1007/s11912-013-0292-x
更新日期：2013-04-01 00:00:00
abstract：PURPOSE OF REVIEW:The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians. RECENT FINDINGS:UC is a rare and aggressive disease with consequent few data about diagnosis and treatment. Dates are mainly based on retrospective trial and case reports with limit...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-0878-z
更新日期：2020-01-27 00:00:00
abstract：:HER2 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases and is involved in the growth, invasion, metastasis, and prognosis of breast cancer. The rationale for prospective trials evaluating the role of anti-HER2 monoclonal antibody therapy for patients with high-risk HER2-positive res...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-001-0073-9
更新日期：2001-11-01 00:00:00
abstract：PURPOSE REVIEW:B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0694-x
更新日期：2018-04-11 00:00:00
abstract：:The majority of patients with ovarian cancer will relapse after initial chemotherapy and will be candidates for salvage treatment. Currently, five agents show clear activity in patients with platinum- and paclitaxel-resistant disease: topotecan, oral etoposide, liposomal doxorubicin, gemcitabine, and, possibly, doceta...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-999-0012-8
更新日期：1999-09-01 00:00:00
abstract：:Postmastectomy radiotherapy continues to be one of the most controversial issues in breast radiotherapy. At the crux of the controversy lies the lack of conclusive studies that specifically address the risk-benefit ratio of postmastectomy radiotherapy for patients at intermediate risk of developing locoregional recurr...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-006-0006-8
更新日期：2006-01-01 00:00:00
abstract：:Particle irradiation of cancerous disease has gained great traction in recent years. The ability for particle therapy centers to deliver radiation with a highly conformal dose distribution while maintaining minimal exit or excess dose delivered to normal tissue, coupled with various biological advantages particularly ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-016-0499-8
更新日期：2016-03-01 00:00:00
abstract：:Chronic opioid therapy (defined as greater than 3 months on opioids) is a common practice for those with non-cancer pain, cancer survivors with treatment-related pain, and individuals with cancer undergoing disease-modifying therapy with a survival that can be for a year or more. Recent studies have found unique long-...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-016-0558-1
更新日期：2016-12-01 00:00:00
abstract：:Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma, comprising approximately 6-8% of all non-Hodgkin lymphomas. MCL is biologically and clinically heterogeneous, and there is no standard treatment for MCL. Although untreated MCL often responds well to frontline combination chemotherapy, relapsed, re...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-015-0460-2
更新日期：2015-08-01 00:00:00
abstract：:In the past, the treatment options for patients with metastatic prostate cancer that progressed despite castrate levels of testosterone was limited, and no therapies provided an improvement in survival. The majority of these patients had extensive osseous disease, multiple comorbidities, and poor performance status. W...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-000-0058-0
更新日期：2000-09-01 00:00:00
abstract：:With our understanding of human papillomavirus (HPV) and cervical cancer, the availability of HPV testing, and the known limitations of cervical cytology, it is time to reassess cervical cancer screening technologies. This article reviews recent randomized trials comparing primary HPV testing with cervical cytology in...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0081-0
更新日期：2008-11-01 00:00:00
abstract：:The prodrug strategy has its own particular real and theoretic obstacles. Clinical strategies and research efforts have tried to approach these problems. The bystander effect, whereby nontransduced cells are affected by simple proximity to those that have received the novel gene, has enabled many prodrug systems to be...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-000-0006-z
更新日期：2000-01-01 00:00:00
abstract：:Chordomas and chondrosarcomas of the skull base are rare, indolent tumors with a natural history of locally invading their surroundings. Safe, maximal resection is the mainstay of treatment, followed by adjuvant radiation therapy. Even with multimodality therapy, local recurrence remains the most common failure patter...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0052-5
更新日期：2008-07-01 00:00:00
abstract：:There has been much development in the field of targeted therapy for melanoma stemming from efforts to decrease treatment-related toxicities and enhance specific cytotoxicity. This review focuses on three modalities of targeted melanoma therapy based on the biology of the targeting mechanism. The first of these modali...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-001-0088-2
更新日期：2001-07-01 00:00:00
abstract：:New combinations of chemotherapy with radiotherapy for gastrointestinal cancers are showing evidence that improved outcomes may result from toxicity profiles associated with "targeted" systemic radiosensitizing agents. These new agents are also clinically attractive owing to such factors as oral bioavailability and pa...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-005-0073-2
更新日期：2005-05-01 00:00:00
abstract：:Gamma-(γ)-herpes virus lymphomas comprise a heterogenous group of B-cell and T-cell neoplasms most commonly associated with Epstein-Barr virus and rarely human herpes virus-8 infection. Adult T-cell leukemia/lymphoma (ATLL) is a unique disease entity caused by the human T-cell lymphotrophic virus, type 1 (HTLV-I), the...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-011-0186-8
更新日期：2011-10-01 00:00:00
abstract：:Management of early endometrial cancer is contentious these days with little agreement between oncologists as well as across MDTs or tumour boards and indeed across countries. This is because of the state of knowledge with regards to risk factors in early endometrial cancer; although we recognise risk factors affect o...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-016-0505-1
更新日期：2016-04-01 00:00:00
abstract：:The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced stage solid tumors has become the standard of care in several instances, particularly for renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors. These agents primarily target...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-012-0242-z
更新日期：2012-08-01 00:00:00
abstract：:Adjuvant treatment of patients with endometrial cancer is tailored to clinical-pathological prognostic factors. Pelvic radiation therapy for stage I endometrial cancer (EC) provides a highly significant improvement of local control, but without survival advantage. Low-risk EC patients have a very favorable prognosis, ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-011-0191-y
更新日期：2011-12-01 00:00:00
abstract：PURPOSE OF REVIEW:Advanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key recent data regarding immune checkpoint inhibitors ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0693-y
更新日期：2018-04-11 00:00:00
abstract：:Glioblastoma multiforme (GBM) is the most common central nervous system malignancy. It is rapidly progressive with rare opportunity for cure. After three decades of laboratory and clinical research, a newly evolved chemoradiotherapy approach using the alkylating agent temozolomide during and after radiotherapy has res...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/BF02951428
更新日期：2007-01-01 00:00:00
abstract：PURPOSE OF REVIEW:Management of metastatic head and neck squamous cell cancers (HNSCC) can be challenging. This review gives an insight of current treatment options for patients with synchronous metastatic HNSCC and suggests a therapeutic algorithm. RECENT FINDINGS:With the rise of novel therapeutic techniques and med...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-019-0856-5
更新日期：2019-11-14 00:00:00
abstract：:For the subgroup of patients with inoperable gastrointestinal stromal tumors, progress has been made by the rapid development and approval of the targeted therapy imatinib mesylate. Small round cell sarcomas (SRCT), such as Ewing/primitive neuroectodermal tumor, desmoplastic SRCT, and rhabdomyosarcoma, are chemotherap...
journal_title：Current oncology reports
pub_type： 杂志文章,收录出版,评审
doi：10.1007/s11912-005-0054-5
更新日期：2005-07-01 00:00:00
